EGFR and neoplasm: Liquid biopsy is one of the most transformative methods, enabling the detection and monitoring of EGFR mutations through circulating tumor DNA (ctDNA) in blood samples, with numerous studies highlighting its clinical utility and concordance with tissue-based genotyping (6, 7).